Monte Rosa Therapeutics Profit Margin

Monte Rosa Therapeutics (GLUE) currently reports a profit margin of -560.85% as of June 2026. That compares with 13.58% in the prior-year period — down 4230.4% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Monte Rosa Therapeutics's profit margin history and peer comparisons.

Monte Rosa Therapeutics's profit margin decreased from 13.58% to -560.85% — a 4230.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Monte Rosa Therapeutics's profit margin of -560.85% is lower than the Healthcare sector average of 21.34%. That is roughly 2728.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Monte Rosa Therapeutics's current -560.85% should be judged against Healthcare norms (sector average: 21.34%) and against GLUE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -560.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Monte Rosa Therapeutics, and consider following GLUE for alerts when major investors trade the stock.